Post-lesion administration of 5-HTIA receptor agonist 8-OH-DPAT protects cholinergic nucleus basalis neurons against NMDA excitotoxicity

NeuroReport

Volumn 14, Issue 1, 2003, Pages 57-60

  Oosterink, Bart J ^a,b   Harkany, Tibor ^a,c   Luiten, Paul G M ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Apoptosis; Glutamate; Neuroprotection; NMDA Receptor; SerotoninIA receptor

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; ACETYLCHOLINESTERASE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; SEROTONIN 1A AGONIST;

ANIMAL EXPERIMENT; ARTICLE; CELL SURVIVAL; CHOLINERGIC NERVE CELL; COGNITION; CONTROLLED STUDY; DRUG EFFECT; LEARNING; MALE; NERVE CELL LESION; NEUROPROTECTION; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; PASSIVE AVOIDANCE; PRIORITY JOURNAL; RAT; SEROTONINERGIC SYSTEM;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ACETYLCHOLINE; ACETYLCHOLINESTERASE; AFFERENT PATHWAYS; ANIMALS; AVOIDANCE LEARNING; BASAL NUCLEUS OF MEYNERT; CELL SURVIVAL; DRUG ADMINISTRATION SCHEDULE; INJECTIONS; INJECTIONS, INTRAPERITONEAL; MALE; N-METHYLASPARTATE; NERVE TISSUE PROTEINS; NEURONS; NEUROPROTECTIVE AGENTS; NEUROTOXINS; RATS; RATS, WISTAR; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; SEROTONIN; SEROTONIN AGONISTS; SOMATOSENSORY CORTEX; STEREOTAXIC TECHNIQUES;

EID: 0037455055     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-200301200-00011     Document Type: Article

References (25)

1. Nicotera P and Lipton SA. J Cerebr Blood Flow Metab 19, 583-591 (1999).
2. De Keyser J, Sulter G and Luiten PGM. Trends Neurosci 22, 535-540 (1999).
3. Khateb A, Fort P, Alortso A et al. Eur J Neurosci 5, 541-547 (1993).
4. Srkalovic G, Selim M, Rea MA et al. Brain Res 656, 302-308 (1994).
5. Whitaker-Azmitia PM, Clarke C and Azmitia EC. Synapse 14, 201-205 (1993).
6. Ablemeyer B and Krieglstein J. Brain Res 777, 179-186 (1997).
7. Ahlemeyer B, Beier H, Semkova I et al. Brain Res 858, 121-128 (2000).
8. De Vry J, Dietrich H, Glaser T et al. Drugs Future 22, 341-349 (1997).
9. Harkany T, Mulder J, Horvath K et al. Neuroscience 108, 629-642 (2001).
10. Chalmers DT and Watson SJ. Brain Res 561, 51-60 (1991).
11. Nyakas C, Oosterink BJ, Keijser J et al. J Chem Neuroanat 13, 53-61 (1997).
12. Oosterink BJ, Korte SM, Nyakas C et al. Eur J Pharmacol 358, 147-152 (1998).
13. Härtig W, Bauer A, Brauer K et al. Rev Neurosci 13, 95-165 (2002).
14. Kása P, Rakonczay Z and Gulya K. Prog Neurobiol 52, 511-535 (1997).
15. Iraizoz I, Guijarro JL, Gonzalo LM et al. Acta Neuropathol 98, 186-196 (1999).
16. Harkany T, O'Mahony S, Keijser J et al. Neurobiol Dis 8, 667-678 (2001).
17. Harkany T, Dijkstra IM, Oosterink BJ et al. Neuroscience 101, 101-114 (2000).
18. Zhou FC, Azmitia EC and Bledsoe S. Dev Brain Res 84, 89-98 (1995).
19. Kline AE, Yu J, Horvath E et al. Neuroscience 106, 547-555 (2001).
20. Mauler F, Fahrig T, Horvath E et al. Brain Res 888, 150-157 (2001).
21. Melena J, Chidlow G and Osborne NN. Eur J Pharmacol 406, 319-324 (2000)
22. Harkany T, O'Mahony S, Kelly JP et al. Behav Brain Res 90, 133-145 (1998).
23. Paxinos G and Watson C. The Rat Brain in Stereotaxic Coordinates, 2nd edn. Sydney: Academic Press; 1989.
24. Hedreen JC, Bacon SJ and Price DL. J Histochem Cytochem 33, 134-140 (1985).
25. Stuiver BT, Douma BR, Bakker R et al. Neurodegeneration 5, 153-159 (1996).